TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Search
Difficulties Chewing and Swallowing
Discover tips on how to overcome difficulties in chewing and swallowing food from Taking Cancer On Through Flavour
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Access to Healthcare: How we help underserved communities
Access to healthcare is not a given for everyone. We are partnering with an organization in Rome to help underserved communities.
Veganism
Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Sore Mouth or Throat
Discover tips on how to take care of a sore mouth or throat from Taking Cancer On Through Flavour
Spain
Our facility in Spain is home to Regulatory Affairs Services and two technology hubs. Explore career opportunities in Spain or our 170 global locations.
Smart scanners to spot fleas and ticks on your pet
How to identify fleas and ticks? With technology, vets can now spot pet parasites with high-definition videos in real time.
Really Digital, Mr Hach!
The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
BI Newsletter_Dec_2016_FINAL.pdf
Avinew
In broiler chickens from the age of one day of age: active immunisation against Newcastle disease to reduce mortality and clinical signs associated with the disease.
Our colleague Trent on how his purpose transformed his life
Trent, a Professional Services Veterinarian, found his purpose in creating an environment that fosters mental and physical wellbeing for others and himself
Global Computational Biology & Digital Sciences
Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Transforming pig farming through AI
With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
Clinical Studies
Clinical Studies
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Ridgefield
Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential